Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 July 2021Website:
http://immuneering.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:59:35 GMTDividend
Analysts recommendations
Institutional Ownership
IMRX Latest News
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104's path to U.S. FDA submission for PDAC - - Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer - - Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 - CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy.
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What type of business is Immuneering?
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
What sector is Immuneering in?
Immuneering is in the Healthcare sector
What industry is Immuneering in?
Immuneering is in the Biotechnology industry
What country is Immuneering from?
Immuneering is headquartered in United States
When did Immuneering go public?
Immuneering initial public offering (IPO) was on 30 July 2021
What is Immuneering website?
https://immuneering.com
Is Immuneering in the S&P 500?
No, Immuneering is not included in the S&P 500 index
Is Immuneering in the NASDAQ 100?
No, Immuneering is not included in the NASDAQ 100 index
Is Immuneering in the Dow Jones?
No, Immuneering is not included in the Dow Jones index
When was Immuneering the previous earnings report?
No data
When does Immuneering earnings report?
The next expected earnings date for Immuneering is 28 February 2025